LAUSR

Recent years have brought exciting new insights in the field of primary hyperoxaluria (PH), both on a basic research level, as well as through the progress of novel therapeutics in clinical development. To date only very few supportive measures are available for patients suffering from PH, which, together with the severity of the disorder, make disease management challenging. Basic and clinical research and development efforts range from correcting the underlying gene mutations, preventing calcium oxalate crystal-induced kidney damage, to the administration of probiotics favouring the intestinal secretion of excess oxalate. In this review, current advances in the development of those strategies are presented and discussed.